MRIdian "RADAR" Trial

NCT ID: NCT06077071

Last Updated: 2025-09-09

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-12-01
• Study Completion Date: 2029-12-01

Brief Summary

The main purpose of this study is to see if treating cancer with the magnetic resonance imaging guided adaptive radiotherapy (MRIdian) can control patient's tumor and eliminate the need for surgery used to treat nerves in the spine flattened by pressure (compressed).

Conditions

Metastatic Epidural Spinal Cord Compression; Spinal Cord Compression

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ViewRay MRidian

Participants will receive five (5) doses of radiation therapy over four (4) weeks. The first dose will be given during week 1; after at least 36 hours from the first dose, participants will receive the second dose. The remaining doses will be three (3) doses will be administered once per week during weeks 2, 3, and 4. The treatment plan may change at the discretion of the treating physician. Participants will have three additional doses each week in Weeks 2, 3, and 4.

Group Type: EXPERIMENTAL

ViewRay MRIdian Stereotactic Radiosurgery

Intervention Type: RADIATION

Participants will undergo stereotactic radiosurgery of the spinal cord on the ViewRay MRIdian, a hybrid MRI-linac platform, with 40 Gy in 5 fractions prescribed to the planning target volume (PTV).

Interventions

ViewRay MRIdian Stereotactic Radiosurgery

Participants will undergo stereotactic radiosurgery of the spinal cord on the ViewRay MRIdian, a hybrid MRI-linac platform, with 40 Gy in 5 fractions prescribed to the planning target volume (PTV).

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

1. Male and female participants ages ≥ 18.

2. Solid tumors causing MESCC for which surgery is an option as first-line treatment.

3. Tumor histologies eligible for treatment include breast, prostate, sarcoma, melanoma, gastrointestinal types, NSCLC and renal cancers. Other solid malignancy types are also allowed at discretion of investigator if not specifically excluded by criteria.

4. MRI of involved spine within 4 weeks prior to registration to determine extent of spine involvement.

5. Bilsky scale ≥ 1c MESCC with tumor ≤ 1 mm from the spinal cord or cauda equina nerve roots anywhere from C1 to terminus of cauda equina on screening MRI.

6. Protocol defined MESCC must involve no more than 3 contiguous vertebral levels. MESCC can involve multiple non-contiguous spinal canal regions within those 3 contiguous vertebral levels.

7. Karnofsky performance score ≥60

8. Survival prognosis ≥3 months

9. Medical status allowing surgery.

10. Neurologic exam within 1 week prior to registration and again within 1 week of first treatment to rule out severe neurologic deficits caused by disease at site of cord compression.

11. Patients with mild to moderate cord neurologic signs are eligible if they are improved or stabilized by steroid. These neurologic signs include radiculopathy, dermatomal sensory change, and muscle strength of involved extremity 4/5 (lower extremity for ambulation or upper extremity for raising arms and/or arm function).

12. All patients must be ambulatory.

13. Numerical Rating Pain Scale within 1 week prior to registration (back pain permitted for enrollment)

14. Spine instability neoplastic score < 14

a. An exception to this criterion may be made if the patient is evaluated by a spinal surgeon and the surgeon defers surgery.

15. Willing and able to undergo daily MRI during treatment

16. Willingness and able to use an acceptable method of contraception during the study and for at least 6 months after stopping the therapy.

17. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

18. History and physical within 2 weeks prior to registration

19. Patients must provide study specific informed consent prior to study entry.

Exclusion Criteria

1. Unknown primary histology

2. Patients with rapid neurologic decline.

3. Bony retropulsion causing neurologic abnormality

4. Non-ambulatory patients.

5. Prior radiation to the involved site.

6. Inability to have an MRI

7. Pre-existing or concomitant neurological problems not related directly to MESCC (e. g., neurologic deficits due to brain metastases)

8. Very radiosensitive tumor histology (e.g., myeloma, seminoma, germ cell tumors, leukemia, and lymphoma)

9. Patients with impaired decision-making capacity.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Viewray Inc.

INDUSTRY

Sponsor Role: collaborator

University of Miami

OTHER

Sponsor Role: lead

Responsible Party

Benjamin Spieler

Assistant Professor of Clinical

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Benjamin Spieler, MD

Role: PRINCIPAL_INVESTIGATOR

University of Miami

Locations

University of Miami

Miami, Florida, United States

Countries

United States

Central Contacts

Benjamin Spieler, MD

Role: CONTACT

bxs737@med.miami.edu

305-243-4229

Facility Contacts

Benjamin Spieler, MD

Role: primary

bxs737@med.miami.edu

305-243-4229

Other Identifiers

20221377

Identifier Type: -

Identifier Source: org_study_id